Common TitleHPTN 084 (LIFE Study)
Official Title A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Phase Phase III
ClinicalTrials.gov NCT03164564
Treatments
Cabotegravir
Cabotegravir
Tradename:ApretudeOther Names:Injectable cabotegravir, Long-acting injectable cabotegravirClass:Integrase Inhibitors (INSTI)Categories PREP
Funding
IndustryViiV Healthcare
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID and Bill and Melinda Gates Foundation
References
- Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779–89.